Prevalence and impact of COVID-19 in Parkinson’s disease: evidence from a multi-center survey in Tuscany region

Prete, Eleonora Del; Francesconi, Alessio; Palermo, Giovanni; Mazzucchi, Sonia; Frosini, Daniela; Morganti, Riccardo; Coleschi, Piero; Raglione, Laura Maria; Vanni, Paola; Ramat, Silvia; Novelli, Alessio; Napolitano, Alessandro; Battisti, Carla; Giuntini, Martina; Rossi, C. A.; Menichetti, Chiara; Ulivelli, Monica; Franco, Valentino De; Rossi, Símone; Bonuccelli, Ubaldo; Ceravolo, Roberto

doi:10.1007/s00415-020-10002-6

Cited by 76 publications

(135 citation statements)

References 28 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…Although prior studies have reported higher SARS-CoV-2-related mortality in patients with PD or dementia compared to patients without preexisting neurodegenerative diseases, 6,7 encouragingly, our comparably relatively large, well-controlled, standardized data set with prospective patient enrollment does not support the notion of an increased risk for a fatal course of SARS-CoV-2 in PD or dementia patients, when treated in tertiary referral centers. Further research is required to shed light on the impact of gender on the outcome of SARS-CoV-2 infections in dementia patients.…”

contrasting

confidence: 72%

Outcomes of SARS‐CoV‐2 Infections in Patients with Neurodegenerative Diseases in the LEOSS Cohort

Huber

Raichle²,

Lingor

et al. 2021

Movement Disorders

View full text Add to dashboard Cite

The impact of preexisting neurodegenerative diseases on superimposed SARS-CoV-2 infections remains controversial. Here we examined the course and outcome of SARS-CoV-2 infections in patients affected by Parkinson's disease (PD) or dementia compared to matched controls without neurodegenerative diseases in the LEOSS (Lean European Open Survey on SARS-CoV-2-infected patients) cohort, a large-scale prospective multicenter cohort study. 1 The LEOSS scientific data set comprises anonymous data after data quality control, including plausibility checks. Collected data include demographic information, standardized clinical classification of the SARS-CoV-2 severity (hospitalization and discharge), administered medical care (eg, intensive care unit [ICU] stay, and ventilation), preexisting and concomitant signs and symptoms, medication, laboratory parameters, and mortality. The patient sample age is grouped in decades. Our study population comprised n = 4310 SARS-CoV-2infected patients (59% men). Forty of them had PD (median decade: 76-85 years, 63% men); 290 had dementia (median decade: 76-85 years, 50% men) (Supplementary Tables S1 and S2). Dementia was classified into Alzheimer's disease (22.1%), vascular dementia (13.3%), other dementia (12.4%), and unknown/missing value (52.1%). More than 95% of the patients were from tertiary referral centers in Germany between March 2020 and November 2020. Using a systematic sampling strategy, we extracted 15 controls randomly from the study population for each PD patient (1:15) and 2 randomly selected controls for each dementia patient (1:2). Any potentially confounding effects resulting from variability in age and sex were fully adjusted for by the matching procedure. To avoid bias, we handled patients and controls the same way according to standard epidemiological principles.

show abstract

contrasting

confidence: 72%

Outcomes of SARS‐CoV‐2 Infections in Patients with Neurodegenerative Diseases in the LEOSS Cohort

Huber

Raichle²,

Lingor

et al. 2021

Movement Disorders

View full text Add to dashboard Cite

show abstract

“…A single-centre, case-controlled telephone survey indicated that morbidity and mortality in patients with mild to moderate PD did not differ from those in the general population [ 22 ]. Conversely, a later phone survey showed that the COVID-19 prevalence among PD patients in Italy is higher than the national average [ 23 ]. These studies provide useful insights into the vulnerability of PD patients, but several methodological inconsistencies hamper their interpretation.…”

Section: Introductionmentioning

confidence: 99%

Alzheimer’s and Parkinson’s Diseases Predict Different COVID-19 Outcomes: A UK Biobank Study

Travaglio

Popovic

et al. 2021

Geriatrics

View full text Add to dashboard Cite

In December 2019, a coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began infecting humans, causing a novel disease, coronavirus disease 19 (COVID-19). This was first described in the Wuhan province of the People’s Republic of China. SARS-CoV-2 has spread throughout the world, causing a global pandemic. To date, thousands of cases of COVID-19 have been reported in the United Kingdom, and over 45,000 patients have died. Some progress has been achieved in managing this disease, but the biological determinants of health, in addition to age, that affect SARS-CoV-2 infectivity and mortality are under scrutiny. Recent studies show that several medical conditions, including diabetes and hypertension, increase the risk of COVID-19 and death. The increased vulnerability of elderly individuals and those with comorbidities, together with the prevalence of neurodegenerative diseases with advanced age, led us to investigate the links between neurodegeneration and COVID-19. We analysed the primary health records of 13,338 UK individuals tested for COVID-19 between March and July 2020. We show that a pre-existing diagnosis of Alzheimer’s disease predicts the highest risk of COVID-19 and mortality among elderly individuals. In contrast, Parkinson’s disease patients were found to have a higher risk of SARS-CoV-2 infection but not mortality from COVID-19. We conclude that there are disease-specific differences in COVID-19 susceptibility among patients affected by neurodegenerative disorders.

show abstract

“…11 Conversely, another telephone survey suggested a higher prevalence of COVID-19 compared with that expected for the general population. 15 Trying to overcome the limitations of these studies, we designed a population-based study investigating the risk for hospital admission of COVID-19 and the risk of death in people with PD or PS.…”

mentioning

confidence: 99%

Risk of Hospitalization and Death for COVID‐19 in People with Parkinson's Disease or Parkinsonism

et al. 2020

View full text Add to dashboard Cite

Background The risk of COVID‐19 and related death in people with Parkinson's disease or parkinsonism is uncertain. The aim of the study was to assess the risk of hospitalization for COVID‐19 and death in a cohort of patients with Parkinson's disease or parkinsonism compared with a control population cohort, during the epidemic bout (March–May 2020) in Bologna, northern Italy. Methods Participants of the ParkLink study with the clinical diagnosis of Parkinson's disease or parkinsonism and people anonymously matched (ratio 1:10) for sex, age, district, and Charlson Index were included. The hospital admission rate for COVID‐19 (February 26–May 31, 2020) and the death rate for any cause were the outcomes of interest. Results The ParkLink cohort included 696 subjects with Parkinson's disease and 184 with parkinsonism, and the control cohort had 8590 subjects. The 3‐month hospitalization rate for COVID‐19 was 0.6% in Parkinson's disease, 3.3% in parkinsonism, and 0.7% in controls. The adjusted hazard ratio (age, sex, district, Charlson Index) was 0.8 (95% CI, 0.3–2.3, P = 0.74) in Parkinson's disease and 3.3 (1.4–7.6, P = 0.006) in parkinsonism compared with controls. Twenty‐nine of the infected subjects died; 30‐day fatality rate was 35.1%, without difference among the 3 groups. Six of 10 Parkinson's disease/parkinsonism patients had the infection during hospitalization or in a nursing home. Conclusions Parkinson's disease per se probably is not a risk factor for COVID‐19 hospitalization. Conversely, parkinsonism is an independent risk factor probably because of a more severe health status, entailing higher care dependence and placement in high‐infection‐risk accommodations. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society.

show abstract

Prevalence and impact of COVID-19 in Parkinson’s disease: evidence from a multi-center survey in Tuscany region

Cited by 76 publications

References 28 publications

Outcomes of SARS‐CoV‐2 Infections in Patients with Neurodegenerative Diseases in the LEOSS Cohort

Outcomes of SARS‐CoV‐2 Infections in Patients with Neurodegenerative Diseases in the LEOSS Cohort

Alzheimer’s and Parkinson’s Diseases Predict Different COVID-19 Outcomes: A UK Biobank Study

Risk of Hospitalization and Death for COVID‐19 in People with Parkinson's Disease or Parkinsonism

Contact Info

Product

Resources

About